目的 探討金蟬止癢膠囊聯(lián)合富馬酸盧帕他定片治療慢性蕁麻疹的臨床療效。方法 選取2019年2月-2019年6月在長(zhǎng)沙市中醫(yī)醫(yī)院診治的86例慢性蕁麻疹患者，根據(jù)用藥的差別分為對(duì)照組（43例）和治療組（43例）。對(duì)照組口服富馬酸盧帕他定片，10 mg/次，1次/d；治療組在對(duì)照組基礎(chǔ)上口服金蟬止癢膠囊，3 g/次，3次/d。兩組患者均經(jīng)4周治療。觀(guān)察兩組患者臨床療效，同時(shí)比較治療前后兩組患者臨床癥狀評(píng)分、UAS和DLQI評(píng)分及血清白細(xì)胞介素-4（IL-4）、白細(xì)胞介素-17（IL-17）、白三烯（LT）、可溶性血管細(xì)胞黏附分子（sVCAM-1）和干擾素-γ（IFN-γ）水平。結(jié)果 治療后，對(duì)照組和治療組臨床有效率分別為81.40%和97.67%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。經(jīng)治療，兩組患者癥狀積分、UAS評(píng)分、DLQI評(píng)分均明顯下降（P<0.05），且治療組比對(duì)照組下降更明顯（P<0.05）。經(jīng)治療，兩組患者血清IL-4、IL-17、LT、sVCAM-1水平均顯著降低（P<0.05），而IFN-γ水平明顯升高（P<0.05），且治療組患者這些血清學(xué)指標(biāo)水平明顯好于對(duì)照組（P<0.05）。結(jié)論 金蟬止癢膠囊聯(lián)合富馬酸盧帕他定片治療慢性蕁麻疹可有效改善患兒臨床癥狀，降低機(jī)體炎癥因子水平，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Jinchan Zhiyang Capsules combined with Rupatadine Fumarate Tablets in treatment of chronic urticaria. Methods Patients (86 cases) with chronic urticaria in Changsha Hospital of Traditional Chinese Medicine from February 2019 to June 2019 were divided into control (43 cases) and treatment (43 cases) groups based on different treatments. Patients in the control group were po administered with Peramivir and Sodium Chloride Injection, 10 mg/time, once daily. Patients in the treatment group were po administered with Jinchan Zhiyang Capsules on the basis of the control group, 3 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the clinical symptom scores, UAS and DLQI score, the serum level of IL-4, IL-17, LT, IFN-γ and sVCAM-1 in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 81.40% and 97.67%, respectively, and there were differences between two groups (P<0.05). After treatment, the clinical symptom scores, UAS and DLQI score in two groups were significantly decreased (P<0.05), and these scores in the treatment group were significantly lower than that in the control group (P<0.05). After treatment, the serum level of IL-4, IL-17, LT and sVCAM-1 in two groups was significantly decreased (P<0.05), but the level of IFN-γ level was significantly increased (P<0.05), and the serological indexes level in the treatment group was significantly better than that in the control group (P<0.05). Conclusion Jinchan Zhiyang Capsules combined with Rupatadine Fumarate Tablets in treatment of chronic urticaria can effectively improve the clinical symptoms, reduce the level of inflammatory factors, which has a certain clinical application value.

R986